阿尔茨海默病和其他类型痴呆症的生物标志物：下一步走向病理生理学以支持临床实践和药物研发。
Biomarkers in Alzheimer Disease and Other Dementias: What's Next into Pathophysiology to Support Clinical Practice and Drug Development.
机构信息
1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, 72-74 Vassilisis Sofia's Avenue, 11528 Athens, Greece.
出版信息
Medicina (Kaunas). 2022 Sep 30;58(10):1374. doi: 10.3390/medicina58101374.
Abstract
Neurodegenerative diseases are a heterogeneous group of disorders characterized by gradual progressive neuronal loss in the central nervous system [...].
摘要
神经退行性疾病是一组异质性疾病，其特征是中枢神经系统中神经元逐渐进行性丧失[...]。
相似文献
1
Biomarkers in Alzheimer Disease and Other Dementias: What's Next into Pathophysiology to Support Clinical Practice and Drug Development.阿尔茨海默病和其他类型痴呆症的生物标志物：下一步走向病理生理学以支持临床实践和药物研发。
Medicina (Kaunas). 2022 Sep 30;58(10):1374. doi: 10.3390/medicina58101374.
2
Value-Generating Exploratory Trials in Neurodegenerative Dementias.神经退行性痴呆的产生价值探索性试验。
Neurology. 2021 May 18;96(20):944-954. doi: 10.1212/WNL.0000000000011774. Epub 2021 Mar 5.
3
Blood and CSF biomarkers for AD revisited: what's new, what's good, and is this where we should be looking?重新审视用于阿尔茨海默病的血液和脑脊液生物标志物：有哪些新进展、哪些是好的，以及这是我们应该关注的方向吗？
Neurobiol Aging. 2002 Jul-Aug;23(4):517-9; discussion 521-2. doi: 10.1016/s0197-4580(01)00349-9.
4
What's hot, what's not, in dementia drugs? Part I: Cholinergic therapies.痴呆症药物领域的热门与冷门？第一部分：胆碱能疗法。
J Gerontol Nurs. 1997 Sep;23(9):52-4. doi: 10.3928/0098-9134-19970901-12.
5
Nonsteroidal anti-inflammatory drugs and Alzheimer disease: what's next?非甾体抗炎药与阿尔茨海默病：下一步何去何从？
JAMA. 2003 Jun 4;289(21):2865-7. doi: 10.1001/jama.289.21.2865.
6
An Overview of Primary Dementias as Clinicopathological Entities.作为临床病理实体的原发性痴呆概述。
Semin Neurol. 2019 Apr;39(2):153-166. doi: 10.1055/s-0039-1683445. Epub 2019 Mar 29.
7
Blood biomarkers for Alzheimer's disease and related disorders.阿尔茨海默病及相关疾病的血液生物标志物。
Acta Neurol Scand. 2022 Jul;146(1):51-55. doi: 10.1111/ane.13628. Epub 2022 Apr 25.
8
Accelerating Alzheimer's disease drug discovery and development: what's the way forward?加速阿尔茨海默病药物发现和开发：前路在何方？
Expert Opin Drug Discov. 2021 Jul;16(7):727-735. doi: 10.1080/17460441.2021.1887132. Epub 2021 Mar 2.
9
Overview of therapeutic targets in management of dementia.痴呆症治疗靶点概述。
Biomed Pharmacother. 2022 Aug;152:113168. doi: 10.1016/j.biopha.2022.113168. Epub 2022 Jun 11.
10
What's hot, what's not, in dementia drugs. Part II.痴呆症药物的热门与冷门。第二部分。
J Gerontol Nurs. 1997 Dec;23(12):46-7. doi: 10.3928/0098-9134-19971201-11.
本文引用的文献
1
Silent Pauses and Speech Indices as Biomarkers for Primary Progressive Aphasia.沉默停顿和言语指数可作为原发性进行性失语症的生物标志物。
Medicina (Kaunas). 2022 Sep 27;58(10):1352. doi: 10.3390/medicina58101352.
2
Initial Data and a Clinical Diagnosis Transition for the Aiginition Longitudinal Biomarker Investigation of Neurodegeneration (ALBION) Study.Aiginition 纵向神经退行性变生物标志物研究（ALBION）的初始数据和临床诊断转换。
Medicina (Kaunas). 2022 Aug 30;58(9):1179. doi: 10.3390/medicina58091179.
3
Rosinidin Protects Streptozotocin-Induced Memory Impairment-Activated Neurotoxicity by Suppressing Oxidative Stress and Inflammatory Mediators in Rats.罗辛定通过抑制氧化应激和炎症介质来保护链脲佐菌素诱导的记忆障碍激活的神经毒性。
Medicina (Kaunas). 2022 Jul 26;58(8):993. doi: 10.3390/medicina58080993.
4
Classical Cerebrospinal Fluid Biomarkers in Dementia with Lewy Bodies.路易体痴呆症的经典脑脊液生物标志物。
Medicina (Kaunas). 2022 Apr 28;58(5):612. doi: 10.3390/medicina58050612.
5
MicroRNA as Candidate Biomarkers in Atypical Parkinsonian Syndromes: Systematic Literature Review.微小 RNA 作为非典型帕金森综合征的候选生物标志物：系统文献综述。
Medicina (Kaunas). 2022 Mar 26;58(4):483. doi: 10.3390/medicina58040483.
6
Role of Biomarkers for the Diagnosis of Prion Diseases: A Narrative Review.用于朊病毒病诊断的生物标志物的作用：叙述性综述。
Medicina (Kaunas). 2022 Mar 25;58(4):473. doi: 10.3390/medicina58040473.
7
Serum NfL in Alzheimer Dementia: Results of the Prospective Dementia Registry Austria.阿尔茨海默病患者血清 NfL：奥地利前瞻性痴呆登记研究结果。
Medicina (Kaunas). 2022 Mar 16;58(3):433. doi: 10.3390/medicina58030433.
8
Synuclein in neurodegeneration.神经退行性变中的突触核蛋白。
Adv Clin Chem. 2021;103:97-134. doi: 10.1016/bs.acc.2020.08.007. Epub 2020 Oct 20.
9
The global burden of neurological disorders.神经疾病的全球负担。
Lancet Neurol. 2019 May;18(5):418-419. doi: 10.1016/S1474-4422(19)30029-8. Epub 2019 Mar 14.
10
A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.一个由九种脑脊液生物标志物组成的小组可能可以识别出具有非典型帕金森综合征的患者。
J Neurol Neurosurg Psychiatry. 2015 Nov;86(11):1240-7. doi: 10.1136/jnnp-2014-309562. Epub 2015 Jan 14.
Zotero 插件